The group was subsequently split into three independent companies: Diaverum, which operated the Gambro dialysis clinics was deemed non-core and was divested to Bridgepoint in 2007.
The blood component technologies unit, Caridian BCT, increased sales by more than 10 %. EBITDA was almost doubled during EQT’s ownership. R&D investments were significant and Caridian BCT strengthened its position in the important growth areas of Pathogen Reduction and Whole Blood Processing. In 2011, Caridian BCT was sold to listed Japanese medical technology company Terumo Corporation for a total enterprise value of USD 2,625 million. Caridian BCT is now the platform for Terumo’s blood technology operations.
The remaining part, Gambro, was the largest and oldest part of the original group and a leader in developing, manufacturing and supplying products and therapies for Kidney and Liver dialysis, Myeloma Kidney Therapy, and other extracorporeal therapies for Chronic and Acute patients. Gambro delivers solutions for In-center Care and Self Care haemodialysis, Renal Intensive Care and Hepatic Care. Dialysis saves the lives of a growing number of patients every year and the only current alternative to renal dialysis is kidney transplantation.
Gambro was sold to US listed medical technology group Baxter International Inc in 2013 for an enterprise value of SEK 26.5 billion.